Viatris Operating Expenses 2010-2025 | VTRS

Viatris operating expenses for the twelve months ending March 31, 2025 were $17.406B, a 17.68% increase year-over-year.

  • Viatris annual operating expenses for 2024 were $14.729B, a 0.47% increase from 2023.
  • Viatris annual operating expenses for 2023 were $14.661B, a 0.09% increase from 2022.
  • Viatris annual operating expenses for 2022 were $14.648B, a 18.26% decline from 2021.

Viatris Operating Expenses 2010-2025 | VTRS

  • Viatris annual operating expenses for 2024 were $14.729B, a 0.47% increase from 2023.
  • Viatris annual operating expenses for 2023 were $14.661B, a 0.09% increase from 2022.
  • Viatris annual operating expenses for 2022 were $14.648B, a 18.26% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$141.7B
CVS Health (CVS)$78.2B
Elevance Health (ELV)$66.8B
Cencora (COR)$56.9B
DiDi Global (DIDIY)$28B
Labcorp Holdings (LH)$21B
Natera (NTRA)$18.8B
BioMerieux (BMXMF)$16B
EUROFINS SCIENT (ERFSF)$14.7B
ICON (ICLR)$13.6B
CochLear (CHEOY)$13.5B
Solventum (SOLV)$12.9B
Medpace Holdings (MEDP)$12.3B
Revvity (RVTY)$11.7B
Avantor (AVTR)$9.3B
Sonic Healthcare (SKHHY)$9.1B
HealthEquity (HQY)$8.4B
Charles River Laboratories (CRL)$8.2B
Caris Life Sciences,�Inc (CAI)$7.6B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$5B
BrightSpring Health Services (BTSG)$3.7B
Sotera Health (SHC)$3.4B
Surgery Partners (SGRY)$2.8B
Organon (OGN)$2.6B
Concentras Parent (CON)$2.6B
Alignment Healthcare (ALHC)$2.5B
GeneDx Holdings (WGS)$2.4B
Progyny (PGNY)$2B
PACS (PACS)$1.8B